p53 Gene status modulates the chemosensitivity of non-small cell lung cancer cells

Journal of Biomedical Science

Volumn 7, Issue 1, 2000, Pages 64-70

  Lai, Shinn Liang ^a,b   Perng, Reury Perng ^a   Hwang, Jaulang ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

Author keywords

Apoptosis; Cell cycle; Chemosensitivity; Non small cell lung cancer; p53

Indexed keywords

CAMPTOTHECIN; CISPLATIN; ETOPOSIDE; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE; CHEMOSENSITIVITY; DNA DAMAGE; DNA DEGRADATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 0033957264     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1159/000025431     Document Type: Article

References (34)

1. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359:552-554; 1992.
2. Chen J-Y, Funk WD, Wright WE, Shay JW, Minna JD. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8:2159-2166; 1993.
3. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minna JD. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5: 1603-1610;1990.
4. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852; 1993.
5. Doyle LA. Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20:326-337;1993.
6. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539-542;1994.
7. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291;1994.
8. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Liebermann DA. p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage-induced apoptosis. Oncogene 10:2263-2270;1995.
9. Heimdal K, Lothe RA, Lystad S, Holm R, Fossa SD, Borresen AL. No germline TP53 mutations detected in familial and bilateral testicular cancer. Genes Chromosomes Cancer 6:92-97;1993.
10. Jonveaux P, Berger R. Infrequent mutations in the p53 gene in primary human T-cell acute lymphoblastic leukemia. Leukemia 5:839-840; 1991.
11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311;1991.
12. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinoma of the lung. Cancer Res 52:4799-4804; 1992.
13. Kuerbitz SJ, Plunkett BS, Walsh WV, Kanstan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495;1992.
14. Lai SL, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson BE, Mulshine JL, Ihde DC, Kayser K, Gazdar AF. MDR1 gene expression in lung cancer. J Natl Cancer Inst 81: 1144-1150;1989.
15. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoplosis in mouse thymocytes. Nature 362:847-849;1993.
16. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967; 1993.
17. Lowe SW, Bodis S, McClatchey A, Remington L. Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810;1994.
18. Miller CW, Kimon K, Aslo A, Kok K, Yokota J, Buys CHCM, Terada M, Koeffler HP. p53 mutations in human lung tumors. Cancer Res 52:1695-1698;1992.
19. Miller CW, Chumakov A, Said J, Chen DL, Aslo A, Koeffler HP. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8:1815-1824;1993.
20. Milner J, Medcalf EA. Construction of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell 65:765-774;1991.
21. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, Gazdar AF. p53 gene mutations in non-small cell lunger cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180;1992.
22. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 85:2018-2023;1993.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxic assays. J Immunol Methods 65:55-63;1983.
24. Nelson WG, Kastan MB. DNA strand breads: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815-1823;1994.
25. O'Connor PM, Jackman J, Bae I, Myers T, Fan S, Scudiero D, Monks A, Sausville E, Weinstein J, Friend S, Fornace AJJ, Kohn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300; 1997.
26. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831; 1992.
27. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4499;1992.
28. Skladanowski A, Larsen AK. Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: Implications for gene therapy. Cancer Res 57:818-823;1997.
29. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2:1665-1671;1996.
30. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491-494;1989.
31. Tsai C-M, Chang K-T, Perng R-P, Mitsudomi T, Chen M-H, Kadoyama C, Gazdar AF. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/ neu gene expression but not with ras gene mutation. N Natl Cancer Inst 85:897-901;1993.
32. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 70:523-526;1992.
33. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345-347;1991.
34. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB. Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8:2555-2559;1993.